论文部分内容阅读
目的：为了喉癌的早期诊断和预后疗效观察，制备了抗人喉癌多克隆抗体。方法：用间接血球凝集抑制试验和酶联免疫吸附试验（ＥＬＩＳＡ）检测喉癌病人的血清及癌组织中喉癌相关抗原。结果：血清中及喉癌组织中喉癌相关抗原的检出率分别为８３．３％和９４．１％，与对照组相比差异非常显著（Ｐ＜０．０１）。结论：制备的抗人喉癌多克隆抗体可以作为喉癌诊断的标记物
Objective: To prepare the anti-human laryngeal carcinoma polyclonal antibody for early diagnosis and prognosis of laryngeal cancer. Methods: Indirect hemagglutination inhibition test and enzyme-linked immunosorbent assay (ELISA) were used to detect laryngeal cancer-associated antigens in serum and cancer tissues of patients with laryngeal cancer. RESULTS: The detection rates of laryngeal cancer-associated antigens in serum and laryngeal cancer tissues were 83.3% and 94.1%, respectively, which were significantly different from those in the control group (P<0.01). Conclusion: The prepared anti-human laryngeal carcinoma polyclonal antibody can be used as a marker for the diagnosis of laryngeal cancer